Integration and acquisition costs	6 Months Ended
Jun. 30, 2015
IntegrationAndAcquisitionCosts[Abstract]
Integration and acquisition costs	4. Integration and acquisition costs For the three and six months to June 30, 2015 Shire recorded a net credit to integration and acquisition costs of $212.4 million and $136.7 million respectively. The net credit principally comprises (i) costs related to the acquisition and integration of NPS Pharma ($47.8 million and $117.7 million in the three and six months to June 30, 2015 respectively), offset by (ii) a net credit relating to the change in the fair value of contingent consideration liabilities of $258.1 million and $255.7 million in the three and six months to June 30, 2015 respectively. The net credit relating to the change in fair value of contingent consideration liabilities principally relates to the acquisition of Lumena Pharmaceuticals, Inc. (“Lumena”), reflecting a lower probability of success for the SHP625 asset (for the treatment of cholestatic liver diseases) following the receipt of data from certain Phase 2 studies, and the acquisition of Lotus Tissue Repair, Inc. (“Lotus Tissue Repair”), reflecting a lower probability of success for the SHP608 asset (for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”)) as a result of certain preclinical toxicity findings (see note 10 for further details). In the three and six months to June 30, 2014 Shire recorded integration and acquisition costs of $112.1 million and $118.7 million respectively. In the three months to June 30, 2014 the charge comprised an $80.6 million net charge on the fair value of contingent consideration liabilities (principally in relation to the acquisition of SARcode Bioscience Inc. (“SARcode”), reflecting Shire's increased confidence in the SHP606 asset) and $31.5 million relating to the acquisition and integration of ViroPharma. In the six months to June 30, 2014 the charge comprised $97.3 million relating to the acquisition and integration of ViroPharma and a net charge on the fair value of contingent consideration liabilities of $21.4 million (principally in relation to SARcode, as outlined above, offset by credits in relation to the acquisition of FerroKin BioSciences, Inc., reflecting the decision to place the Phase 2 clinical trial for SHP602 on clinical hold).

Integration and acquisition costs

6 Months Ended

Jun. 30, 2015

IntegrationAndAcquisitionCosts[Abstract]

4. Integration and acquisition costs

For the three and six months to June 30, 2015 Shire recorded a net credit to integration and acquisition costs of $212.4 million and $136.7 million respectively. The net credit principally comprises (i) costs related to the acquisition and integration of NPS Pharma ($47.8 million and $117.7 million in the three and six months to June 30, 2015 respectively), offset by (ii) a net credit relating to the change in the fair value of contingent consideration liabilities of $258.1 million and $255.7 million in the three and six months to June 30, 2015 respectively. The net credit relating to the change in fair value of contingent consideration liabilities principally relates to the acquisition of Lumena Pharmaceuticals, Inc. (“Lumena”), reflecting a lower probability of success for the SHP625 asset (for the treatment of cholestatic liver diseases) following the receipt of data from certain Phase 2 studies, and the acquisition of Lotus Tissue Repair, Inc. (“Lotus Tissue Repair”), reflecting a lower probability of success for the SHP608 asset (for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”)) as a result of certain preclinical toxicity findings (see note 10 for further details).

In the three and six months to June 30, 2014 Shire recorded integration and acquisition costs of $112.1 million and $118.7 million respectively. In the three months to June 30, 2014 the charge comprised an $80.6 million net charge on the fair value of contingent consideration liabilities (principally in relation to the acquisition of SARcode Bioscience Inc. (“SARcode”), reflecting Shire's increased confidence in the SHP606 asset) and $31.5 million relating to the acquisition and integration of ViroPharma. In the six months to June 30, 2014 the charge comprised $97.3 million relating to the acquisition and integration of ViroPharma and a net charge on the fair value of contingent consideration liabilities of $21.4 million (principally in relation to SARcode, as outlined above, offset by credits in relation to the acquisition of FerroKin BioSciences, Inc., reflecting the decision to place the Phase 2 clinical trial for SHP602 on clinical hold).